Zepbound works better than Wegovy in weight loss: study
In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy.
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to ...
These Stocks Are Moving the Most Today: Marvell, Salesforce, Pure Storage, Chewy, GM, Roku, Foot Locker, Couchbase, and More
Shares of Marvell Technology and Salesforce rise sharply with earnings from both companies receiving bumps from artificial ...
Investor's Business Daily on MSN50m
Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.Please watch the video at Investors.com - The Weight-Loss ...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug ...
The Independent59m
Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says
We believe quality journalism should be available to everyone, paid for by those who can afford it. In a new head-to-head trial, drugmaker Eli Lilly said Wednesday that patients using its obesity ...